Table 8.
Dwass–Steel–Critchlow–Fligner pairwise comparison based on autonomic adverse effects
| W | p-value | ||
|---|---|---|---|
| Oral muscarinic | Oral adrenergic | − 2.644 | 0.501 |
| Oral muscarinic | Oral serotonergic/dopaminergic | − 2.156 | 0.730 |
| Oral muscarinic | Oral dopaminergic | − 1.544 | 0.931 |
| Oral muscarinic | LAI muscarinic | − 4.247 | 0.043 |
| Oral muscarinic | LAI adrenergic | − 2.696 | 0.476 |
| Oral muscarinic | LAI serotonergic/dopaminergic | − 2.675 | 0.486 |
| Oral adrenergic | Oral serotonergic/dopaminergic | 0.693 | 0.999 |
| Oral adrenergic | Oral dopaminergic | − 1.052 | 0.990 |
| Oral adrenergic | LAI muscarinic | − 2.488 | 0.576 |
| Oral adrenergic | LAI adrenergic | − 1.640 | 0.909 |
| Oral adrenergic | LAI serotonergic/dopaminergic | − 0.208 | 1.000 |
| Oral serotonergic/dopaminergic | Oral dopaminergic | − 1.347 | 0.964 |
| Oral serotonergic/dopaminergic | LAI muscarinic | − 2.969 | 0.353 |
| Oral serotonergic/dopaminergic | LAI adrenergic | − 1.925 | 0.823 |
| Oral serotonergic/dopaminergic | LAI serotonergic/dopaminergic | − 0.783 | 0.998 |
| Oral dopaminergic | LAI muscarinic | 0.000 | 1.000 |
| Oral dopaminergic | LAI adrenergic | − 0.720 | 0.999 |
| Oral dopaminergic | LAI serotonergic/dopaminergic | 0.859 | 0.997 |
| LAI muscarinic | LAI adrenergic | − 0.449 | 1.000 |
| LAI muscarinic | LAI serotonergic/dopaminergic | 2.064 | 0.769 |
| LAI adrenergic | LAI serotonergic/dopaminergic | 1.393 | 0.957 |
LAI long-acting injectable